+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Bovine Ephemeral Fever Vaccines - Global Strategic Business Report

  • PDF Icon

    Report

  • 377 Pages
  • July 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6110807
The global market for Bovine Ephemeral Fever Vaccines was valued at US$74.8 Million in 2024 and is projected to reach US$82.8 Million by 2030, growing at a CAGR of 1.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Bovine Ephemeral Fever Vaccines market.

Global Bovine Ephemeral Fever Vaccines Market - Key Trends & Drivers Summarized

Why Is Bovine Ephemeral Fever Vaccination Critical for Livestock Health and Farm Profitability?

Bovine ephemeral fever (BEF), commonly known as three-day sickness, is a viral disease that significantly impacts cattle health, particularly in tropical and subtropical regions. Characterized by sudden fever, stiffness, lameness, and loss of appetite, the disease typically resolves within a few days but can lead to severe economic losses due to reduced milk production, weight loss, temporary infertility, and increased veterinary costs. In some cases, complications can even result in death, especially in older or more vulnerable animals. Vaccination has emerged as the most effective preventive strategy against BEF, offering protection to entire herds and minimizing productivity disruptions. Given that the disease is transmitted by biting insects such as mosquitoes and midges, its seasonal and regional outbreaks can be hard to predict, making vaccination essential in endemic zones. Livestock farmers in affected areas are increasingly recognizing the importance of preemptive immunization to safeguard herd health and ensure stable income from meat and dairy production. The rising demand for food security, along with growing awareness of zoonotic diseases and their economic implications, further highlights the urgency for robust animal vaccination programs. Bovine ephemeral fever vaccines, whether live attenuated or inactivated, provide a cost-effective tool for reducing disease incidence and improving overall herd resilience. As farming practices modernize and commercial livestock production scales up globally, vaccination is becoming an integral part of disease management and operational planning for cattle-rearing operations.

How Are Advancements in Vaccine Development Enhancing Protection Against Bovine Ephemeral Fever?

Recent innovations in vaccine technology are significantly improving the efficacy, safety, and shelf-life of bovine ephemeral fever vaccines. Traditionally, live attenuated vaccines were widely used, offering strong immune responses but sometimes raising concerns about stability and risk in immunocompromised animals. New-generation vaccines, including inactivated virus formulations and subunit-based options, are addressing these challenges by providing safer alternatives with minimal side effects. These formulations are particularly valuable in regions where transportation and cold-chain logistics are difficult, as advancements in thermostable vaccines reduce the need for constant refrigeration. Molecular research has also led to a better understanding of the BEF virus structure and antigenic components, paving the way for targeted vaccine design and improved diagnostic compatibility. Some manufacturers are exploring recombinant DNA techniques to produce antigens without using the live virus, thereby improving biosafety standards and enabling faster production cycles in response to outbreaks. Additionally, adjuvant technologies have evolved to enhance the immune response and prolong the duration of protection, reducing the need for frequent re-vaccinations. Research into multivalent vaccines that protect against multiple bovine pathogens in a single dose is also gaining ground, offering convenience and broader disease coverage. These technological strides are making BEF vaccines more adaptable to varied climatic and farming conditions, supporting global efforts to control vector-borne cattle diseases more effectively. The integration of data analytics, digital health monitoring, and veterinary mobile applications is further improving vaccination schedules and compliance rates, enhancing the overall impact of immunization programs.

What Regional and Environmental Factors Influence the Demand for BEF Vaccines Worldwide?

The demand for bovine ephemeral fever vaccines varies significantly across regions due to differences in climate, cattle population density, farming practices, and disease prevalence. BEF is most prevalent in parts of Asia, Africa, Australia, and the Middle East, where warm temperatures and high humidity provide ideal conditions for the insect vectors that transmit the virus. In Australia, BEF outbreaks have been historically common in the northern and eastern regions, leading to widespread vaccination programs supported by both public and private veterinary services. Southeast Asian nations like Indonesia, Thailand, and the Philippines also report seasonal outbreaks, prompting government-led awareness campaigns and subsidies for vaccine access. In Africa, where livestock farming is a major livelihood, BEF outbreaks are sporadic but severe, with rural farmers often struggling to access vaccines due to distribution challenges and limited infrastructure. Middle Eastern countries, including Saudi Arabia and Iran, have increased their focus on BEF vaccination to protect growing dairy and beef sectors that are vulnerable to climate-induced disease pressures. In Latin America, the disease is less prevalent but growing concerns about transboundary animal diseases have prompted inclusion of BEF in broader animal health surveillance systems. Environmental changes, including rising temperatures and altered precipitation patterns, are expanding the geographical range of insect vectors, potentially introducing BEF into new regions and prompting preventive vaccination in previously unaffected areas. Regional trade dynamics also influence vaccine demand, as countries with strict livestock health regulations require vaccination certificates for cross-border cattle movements, further incentivizing vaccination uptake in export-oriented farming economies.

What Are the Main Factors Driving the Growth of the Bovine Ephemeral Fever Vaccines Market Globally?

The growth in the bovine ephemeral fever vaccines market is driven by a combination of rising disease prevalence, increasing livestock populations, advancements in vaccine formulation, and expanding veterinary infrastructure. One of the primary factors is the growing awareness among farmers and livestock producers about the economic risks associated with BEF outbreaks, particularly in terms of lost milk yield, reduced fertility, and higher treatment costs. As the global demand for meat and dairy products continues to rise, producers are under increasing pressure to maintain healthy and productive herds, making disease prevention a top priority. Government policies and veterinary health programs are also playing a pivotal role by promoting vaccination through subsidies, awareness campaigns, and mandatory immunization initiatives in high-risk areas. The expansion of commercial livestock farming, especially in Asia-Pacific and parts of Africa, has created a larger market for animal vaccines, supported by better cold-chain logistics and distribution networks. Innovations in vaccine delivery, such as single-dose regimens and thermostable formulations, are further enhancing accessibility and compliance among farmers. In addition, the growing integration of animal health data systems allows for more accurate disease tracking, early warning alerts, and strategic vaccine deployment. Private sector investment in animal biotechnology and international collaborations on veterinary health research are contributing to a more competitive and innovative market landscape. Collectively, these factors are fueling a sustained increase in demand for bovine ephemeral fever vaccines, positioning them as a critical component of global livestock health management and agricultural productivity enhancement.

Scope of the Report

The report analyzes the Bovine Ephemeral Fever Vaccines market, presented in terms of market value (USD). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Type (Live Vaccine, Killed Vaccine, Other Types); Application (Cattle Application, Water Buffaloes Application); End-User (Medical Device Companies End-User, Pharmaceutical End-User, Animal Hospitals End-User, Other End-Users).
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Live Vaccine segment, which is expected to reach US$44.1 Million by 2030 with a CAGR of a 1.4%. The Killed Vaccine segment is also set to grow at 2.0% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $20.4 Million in 2024, and China, forecasted to grow at an impressive 3.4% CAGR to reach $15.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Bovine Ephemeral Fever Vaccines Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Bovine Ephemeral Fever Vaccines Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Bovine Ephemeral Fever Vaccines Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Bayer AG, Biogenesis Bagó, Bioveta a.s., Boehringer Ingelheim Animal Health, Ceva Santé Animale and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 44 companies featured in this Bovine Ephemeral Fever Vaccines market report include:

  • Bayer AG
  • Biogenesis Bagó
  • Bioveta a.s.
  • Boehringer Ingelheim Animal Health
  • Ceva Santé Animale
  • China Animal Husbandry Industry
  • Elanco Animal Health
  • Fatro S.p.A.
  • Hester Biosciences Limited
  • HIPRA
  • Indian Immunologicals Ltd.
  • Intervet (MSD Animal Health)
  • Kyoto Biken Laboratories Inc.
  • Laboratorios Ovejero S.A.
  • Merck & Co., Inc. (MSD AH)
  • Norbrook Laboratories
  • Phibro Animal Health Corporation
  • Vaxxinova
  • Vetoquinol
  • Zoetis Inc.

This edition integrates the latest global trade and economic shifts into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes historical analysis from 2015 to 2023.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025 (E), competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Bovine Ephemeral Fever Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Increasing Outbreak Incidence Throws the Spotlight on Bovine Ephemeral Fever Vaccine Deployment
  • Rising Economic Impact of BEF on Dairy and Beef Cattle Spurs Demand for Preventive Vaccination Programs
  • Here's the Story: How Climate Change and Vector Spread Are Expanding the Geographical Risk Zone for BEF
  • Government-Led Livestock Immunization Campaigns Strengthen Business Case for BEF Vaccine Adoption
  • Growth of Commercial Dairy Farms and Export-Oriented Livestock Sectors Expands Addressable Market for BEF Vaccines
  • Here's How Advances in Adjuvant and Recombinant Vaccine Technologies Are Enhancing BEF Vaccine Efficacy
  • Global Focus on Livestock Health Security Throws the Spotlight on Zoonotic and Vector-Borne Disease Control Measures
  • Rising Cross-Border Animal Movement Sustains Need for Preemptive Immunization Against Outbreak Risk
  • Integration of BEF Vaccination into Multi-Disease Control Strategies Generates Demand for Combination Vaccines
  • Increasing Pressure to Reduce Antibiotic Use in Livestock Promotes Preventive Approaches Like Vaccination
  • Expansion of Cold Chain Logistics Enhances Vaccine Reach in Remote and Climatically Challenging Areas
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Bovine Ephemeral Fever Vaccines Market Analysis of Annual Sales in US$ for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Bovine Ephemeral Fever Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • Table 3: World Historic Review for Bovine Ephemeral Fever Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • Table 4: World 16-Year Perspective for Bovine Ephemeral Fever Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Live Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • Table 6: World Historic Review for Live Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • Table 7: World 16-Year Perspective for Live Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Killed Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • Table 9: World Historic Review for Killed Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • Table 10: World 16-Year Perspective for Killed Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • Table 12: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • Table 13: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Cattle Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • Table 15: World Historic Review for Cattle Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • Table 16: World 16-Year Perspective for Cattle Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Water Buffaloes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • Table 18: World Historic Review for Water Buffaloes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • Table 19: World 16-Year Perspective for Water Buffaloes Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Medical Device Companies End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • Table 21: World Historic Review for Medical Device Companies End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • Table 22: World 16-Year Perspective for Medical Device Companies End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Pharmaceutical End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • Table 24: World Historic Review for Pharmaceutical End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • Table 25: World 16-Year Perspective for Pharmaceutical End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Animal Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • Table 27: World Historic Review for Animal Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • Table 28: World 16-Year Perspective for Animal Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • Table 29: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • Table 30: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • Table 31: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Bovine Ephemeral Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
CANADA
JAPAN
  • Bovine Ephemeral Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
CHINA
  • Bovine Ephemeral Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
EUROPE
  • Bovine Ephemeral Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
FRANCE
  • Bovine Ephemeral Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
GERMANY
  • Bovine Ephemeral Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
ITALY
UNITED KINGDOM
  • Bovine Ephemeral Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Bovine Ephemeral Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
AUSTRALIA
  • Bovine Ephemeral Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Bovine Ephemeral Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Bovine Ephemeral Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Bovine Ephemeral Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Bovine Ephemeral Fever Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Bayer AG
  • Biogenesis Bagó
  • Bioveta a.s.
  • Boehringer Ingelheim Animal Health
  • Ceva Santé Animale
  • China Animal Husbandry Industry
  • Elanco Animal Health
  • Fatro S.p.A.
  • Hester Biosciences Limited
  • HIPRA
  • Indian Immunologicals Ltd.
  • Intervet (MSD Animal Health)
  • Kyoto Biken Laboratories Inc.
  • Laboratorios Ovejero S.A.
  • Merck & Co., Inc. (MSD AH)
  • Norbrook Laboratories
  • Phibro Animal Health Corporation
  • Vaxxinova
  • Vetoquinol
  • Zoetis Inc.

Table Information